Tiziana life sciences files new patent application for combination therapy of anti-cd3 (foralumab) with glp-1 receptor agonist for additional reduction of obesity - associated inflammation

New york, jan. 05, 2024 (globe newswire) -- tiziana life sciences ltd. (nasdaq: tlsa) (“tiziana” or the “company”), a biotechnology company developing breakthrough immunomodulation therapies, today announced filing of a new patent application relating to composition and methods for combining glp-1ra and foralumab, a fully human anti-cd3 antibody, to achieve further reductions in systemic and vascular inflammation associated with type 2 diabetes (t2d) and also in a separate population of patients with non t2d obesity.
TLSA Ratings Summary
TLSA Quant Ranking